[{"id":"7a52caf1-0dfe-4289-a790-01f8d7b2993f","acronym":"DUAL-CAR-NK-GB","url":"https://clinicaltrials.gov/study/NCT07480941","created_at":"2026-03-28T01:39:30.783Z","updated_at":"2026-03-28T01:39:30.783Z","phase":"Phase 1","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","source_id_and_acronym":"NCT07480941 - DUAL-CAR-NK-GB","lead_sponsor":"Beijing Biotech","biomarkers":" EGFR • CD276 • IL13RA2","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR • CD276 • IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/02/2026","start_date":" 02/02/2026","primary_txt":" Primary completion: 02/18/2027","primary_completion_date":" 02/18/2027","study_txt":" Completion: 03/17/2028","study_completion_date":" 03/17/2028","last_update_posted":"2026-03-18"},{"id":"c31fe31a-3823-4e8c-81cc-892c70bccfed","acronym":"","url":"https://clinicaltrials.gov/study/NCT07206849","created_at":"2025-10-11T01:31:02.610Z","updated_at":"2025-10-11T01:31:02.610Z","phase":"Phase 2","brief_title":"Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)","source_id_and_acronym":"NCT07206849","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2025-10-03"}]